ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCTURUS THERAPEUTICS HOLDINGS INC

Explicit Guidance:

• CF Program: Complete fourth cohort Phase 2 data presentation scheduled for Q2 2027; enrollment expected to complete by end of current calendar year.
• OTC Program (ARCT-2601): Clinical trial initiation anticipated early next year (January start); top-line data expected in the second half of 2027.
• PKU Pipeline: IND filing expected in the second half of next year.
• OTC Reformulation Validation: Preliminary safety/tolerability data in a small cohort of six or fewer patients expected to be generated to demonstrate Lunar 2.0 superiority before FDA pivotal trial discussions.
• Financial Milestone: Upon decision to advance CF program to Phase 3, a $40 million milestone payment from Thermo Fisher will be triggered (split due to deal terms).

Business-Segment Outlook:

• Cystic Fibrosis (CF): Targeting the Class 1 population (approx. 15% of global CF, up to 35-40% in specific regions like Turkey/Israel) who lack the CFTR protein entirely. Phase 2 protocol narrowed patient inclusion criteria (FEV1 45-85%) to improve signal detection; aims for FEV1 stabilization or modest inflection to justify Phase 3.
• Ornithine Transcarbamylase (OTC) Deficiency: Pivot from bi-weekly hospital infusion (0.5 mg/kg, 3-hour chair time) to monthly home-based dosing with Lunar 2.0 formulation, targeting lower doses and reduced chair time (<1 hour). Management views this as a potential number one market position in the urea cycle disorder space, revising peak sales potential from "20% of market" to "big player/number one."
• New Indications (PKU): Expansion into Phenylketonuria (PKU) enabled by Lunar 2.0 potency; previously untractable due to frequent dosing requirements.
• Pipeline Velocity: Two major data catalysts in 2027 driving value creation; OTC is described as no longer a "dark horse" but a featured program with higher near-term success likelihood than CF.

Market and Competitive Outlook:

• Delivery Technology: Lunar 2.0 lipid nanoparticle (LNP) technology is 38x more potent than Lunar 1.0 in non-human primates. This differentiation allows for reduced dosing frequency and lower doses, creating a "new standard of care" for liver-targeted therapeutics.
• Competitive Landscape: CF market dominated by modulators (fixing broken transporters) leaving Class 1 (null mutants) unaddressed; Arcturus offers a distinct "gene replacement" approach. OTC market currently served only by ammonia scavengers that fail to normalize glutamine; Arcturus normalizes both ammonia and glutamine.
• Historical Precedent: Management draws parallel to Alnylam's 2012 formulation shift (creating 30x potency improvement) which generated billions in value, suggesting similar value creation potential for Arcturus's Lunar 2.0 validation.
• Market Opportunity: OTC deficiency identified as a multi-billion dollar peak potential opportunity with limited direct competition for mRNA-based cures.

Macro / Industry Outlook:

• Regulatory Environment: Strong engagement and interest from the CF Foundation and regulatory agencies regarding the Class 1 CF program; agency explicitly indicated a desire for a "something" that works in this severe segment.
• Clinical Trial Standards: Anticipated shift toward more rigorous enrollment criteria (reduced baseline variability, tighter screen-to-baseline delta) to overcome historical statistical challenges in small-cohort rare disease trials.
• Partnership Dynamics: Thermo Fisher is taking "at-risk steps" to prepare for Phase 3 as of July, indicating strong industry confidence in Arcturus's trajectory.

Strategic Initiatives:

• Platform Validation: Utilizing the ARCT-2601 (OTC reformulation) to validate Lunar 2.0, which unlocks additional liver indications (PKU) and expands the therapeutic addressable market.
• Geographic Expansion: Active enrollment expansion into Turkey and Israel to access higher prevalence cohorts of Class 1 CF patients.
• Phase 3 Preparation: Leveraging REACH study data from the CF Foundation for statistical powering and trial design of the Phase 3 CF program to minimize cost and time.
• FDA Engagement: Scheduled meetings post-small cohort data to define pivotal trial paths for both stable adult and pediatric OTC populations.

Risks and Headwinds to Outlook:

• Clinical Efficacy Uncertainty: CF trial success depends on observing FEV1 stabilization or improvement; failure to demonstrate signal against the background of natural lung degradation (1.5-2.5% FEV1 loss annually) could halt development.
• Enrollment Challenges: Current enrollment is active but "busy," with variability in patient lung function history requiring two years of prior data for inclusion; success relies on recruiting patients within the 45-85% FEV1 range.
• Data Disclosure Timing: No specific date provided for top-line data release between now and Q2 2027; management retains flexibility to release data concurrently with a Phase 3 go/no-go decision.
• Preclinical to Clinical Translation: While non-human primate data for Lunar 2.0 shows 38x potency, reliance on small animal data (6-9 primates) requires validation in humans to fully confirm superiority over Lunar 1.0.
• Disease Complexity: OTC deficiency presents X-linked severity differences (females stable, males pediatric) requiring distinct pivotal trial pathways.

Management Tone on the Future:

• High Confidence: Expressed strong excitement and confidence in the 2027 timeline, describing it as "12 years in the making" with "fruits of labor" emerging.
• Differentiation: Management emphasizes the unique 38x potency of Lunar 2.0 as a "luxury" in the field, creating a sense of competitive advantage and urgency.
• Value Creation: Tone suggests immediate value creation potential, drawing parallels to historical biotech inflection points (Alnylam 2012) and anticipating a "major" inflection point in 2027.
• Strategic Clarity: Management has moved from general optimism to specific guidance on data presentation dates, indicating a more mature and confident stage in the development process.

Miscellaneous:

• Previous Product Safety: ARCT-2601's predecessor (ARCT-810) has an established safety and tolerability profile in stable adults, providing a strong foundation for the reformulated version.
• Dosing Logistics: Potential shift from 3-hour clinic visits to <1 hour home/nurse-administered visits for OTC patients, significantly improving patient convenience and compliance.
• Regulatory Collaboration: The CF Foundation is actively tracking hundreds of Class 1 subjects (REACH study), and Arcturus has insights into this data to inform their Phase 3 design.